For many rare conditions, there is limited understanding of the real-world impacts faced by patients and their families. To ...

Tedros Adhanom Ghebreyesus, WHO Director-General, commented: “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it. WHO ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

AstraZeneca’s Andrea Mugan shares her unique perspectives on patients, experience, change and challenges ...

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage in the UK’s medicines manufacturing ...

Dundee-based Ubiquigent Limited and San Francisco’s Alleo Labs Corp have entered a strategic partnership to advance deubiquitinase (DUB)-focused drug discovery using AI. The collaboration aims to ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at White City Place, a biotech hub in London home to ...

Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based immunotherapies for cancer, has announced that its phase 2 trial of TG4001 in ...

Lundbeck has announced a significant step forward in its Focused Innovator strategy with the acquisition of Longboard Pharmaceuticals. This strategic deal, valued at approximately USD 2.6 billion, ...

Make no mistake, innovation in diabetes care is critical. Diabetes never takes a break. People with diabetes manage their condition on their own, 365 days a year – making multiple therapy decisions ...